Table 2. Univariate analyses of clinicopathological variables affecting disease-free survival.

Variables	Total (n = 681)			*Lymph node positive (n = 209)			*Lymph node negative (n = 472)
	HR	95% CI	p value	HR	95% CI	pvalue	HR	95% CI	p value
Histological grade: 3 vs. 1/2	0.823	0.541–1.251	0.360	1.094	0.568–2.110	0.788	0.583	0.332–1.022	0.059
Pathological T stage: 3/4 vs. 1/2	3.591	1.926–6.695	<0.001	2.129	1.009–4.492	0.047	4.406	1.374–14.131	0.013
Lymph node metastasis: positive vs. negative	2.709	1.867–3.933	<0.001
Lymphovascular invasion: positive vs. negative	3.341	2.302–4.851	<0.001	2.703	1.535–4.760	0.001	2.343	1.231–4.458	0.010
TILs: 10% increments	0.982	0.974–0.989	<0.001	0.964	0.964–0.987	<0.001	0.985	0.974–0.995	0.005
TLSs adjacent to invasive area: moderate to severe vs. no or mild	0.492	0.336–0.720	<0.001	0.354	0.210–0.594	<0.001	0.678	0.381–1.208	0.184
MHC-I expression: high vs. low or no	0.917	0.631–1.333	0.651	0.716	0.425–1.206	0.210	1.170	0.679–2.014	0.572
MHC-II expression: positive vs. negative	0.713	0.460–1.107	0.130	0.400	0.196–0.814	0.012	1.131	0.635–2.013	0.677
PD-L1 expression: positive vs. negative	0.487	0.198–1.195	0.116	0.620	0.194–1.984	0.416	0.394	0.096–1.620	0.197
MxA expression: high vs. low	0.505	0.327–0.779	0.002	0.577	0.316–1.054	0.074	0.479	0.256–0.896	0.021
PKR expression: high vs. low	0.836	0.573–1.219	0.352	0.793	0.468–1.342	0.387	0.862	0.502–1.480	0.590

CI, confidence interval; HR, hazard ratio; MHC, major histocompatibility complex; MxA, myxovirus resistance gene A; PKR, double-stranded RNA-activated protein kinase; TILs, tumor-infiltrating lymphocytes; TLSs, tertiary lymphoid structures.

*In the columns, lymph node positive and negative refer to patients who have and do not have lymph node metastasis, respectively.